TJ DaRenTang USD: Annual Reports and Related Documents

Singapore ExchangeMay 28 17:06 · Announcements

Tianjin Pharmaceutical's Q1 Attributable Profit Slips 3%

Tianjin Pharmaceutical (SGX:T14) posted an attributable profit of 387.3 million yuan in the first quarter, down 3% from 400.8 million yuan a year earlier. Earnings per share in the three months ended

MT NewswiresApr 30 13:01

Express News | Da Ren Tang: Net profit from mother for the first quarter was 387 million yuan, down 3.36% year on year

BreakingsApr 29 16:04

Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.

Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.

Zhitong FinanceApr 22 09:52

Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significa

Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significant growth in core products; 2) steady improvement in profitability; and 3) impressive growth in overseas markets. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 19 19:47

A-share changes | Daren Tang rose 8% in the afternoon, and industrial revenue reached a new high last year

Glonghui, April 1 | Daren Tang (600329.SH) increased its increase to 8% in the afternoon, and the stock price returned to the 30 yuan mark, with a total market value of 23.08 billion yuan. The company announced after the market on Friday that net profit for 2023 was 987 million yuan, an increase of 14.49% over the previous year, and plans to distribute 10 12.8 yuan. Among them, the company's industrial revenue was 4.930 billion yuan, maintaining double-digit year-on-year growth and reaching a new high. According to Fangzheng Securities reviews, the company has achieved remarkable results in deepening its core products, and its performance has exceeded expectations. Maintain a “Recommended” rating.

Gelonghui FinanceApr 1 13:56